Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects

被引：0
|
作者：
Rebecca E. Wrishko
Jacqueline B. McCrea
Ka Lai Yee
Wen Liu
Deborah Panebianco
Eric Mangin
Manu Chakravarthy
Maria P. Martinez-Cantarin
Walter K. Kraft
机构：
[1] Merck & Co.,Department of Pharmacology and Experimental Therapeutics
[2] Inc.,undefined
[3] Thomas Jefferson University,undefined
来源：
Clinical Drug Investigation | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The original version of this article unfortunately contained a mistake
引用
收藏
页码：453 / 454
页数：1
相关论文
共 50 条
  • [1] Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects (vol 39, pg 441, 2019)
    Wrishko, Rebecca E.
    McCrea, Jacqueline B.
    Yee, Ka Lai
    Liu, Wen
    Panebianco, Deborah
    Mangin, Eric
    Chakravarthy, Manu
    Martinez-Cantarin, Maria P.
    Kraft, Walter K.
    CLINICAL DRUG INVESTIGATION, 2019, 39 (05) : 453 - 454
  • [2] Effects of CYP3A4 inhibition/induction, and OATP inhibition on the pharmacokinetics of atogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover trials
    Boinpally, R.
    Chen, W.
    McGeeney, D.
    Trugman, J. M.
    HEADACHE, 2022, 62 : 107 - 107
  • [3] Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects
    Linlin Hu
    Ting Dou
    Qiuyue Sun
    Lu Tang
    Mingmin Cai
    Wei Qian
    Huiping Wang
    Investigational New Drugs, 2023, 41 : 276 - 283
  • [4] Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects
    Hu, Linlin
    Dou, Ting
    Sun, Qiuyue
    Tang, Lu
    Cai, Mingmin
    Qian, Wei
    Wang, Huiping
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (02) : 276 - 283
  • [5] AN OPEN-LABEL, 2-PERIOD, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF LOPERAMIDE ON THE PHARMACOKINETICS OF NERATINIB IN HEALTHY SUBJECTS.
    Keyvanjah, K.
    Martin, D.
    Cooke, B.
    Sterling, L.
    Liang, J.
    Olek, E.
    Rubets, I.
    Wong, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S73 - S73
  • [6] Pharmacokinetics of Sugammadex: An Open-Label, 3-Period, Fixed-Sequence, 3-Single-Doses Study in Healthy Chinese Subjects
    Yuan, Fei
    Yang, Mengjie
    Chen, Weili
    Chen, Hanjing
    Xu, Hongrong
    Li, Hui
    Sheng, Lei
    Li, Xuening
    Ellen Wrishko, Rebecca
    Joel Woolf, Eric
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (03): : 333 - 340
  • [7] The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
    Vourvahis, Manoli
    Plotka, Anna
    Kantaridis, Constantino
    Fang, Annie
    Heera, Jayvant
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (05) : 564 - 570
  • [8] A phase I open-label, fixed-sequence, two-period crossover study of the effect of multiple doses of Itraconazole on Palbociclib (PD-0332991) pharmacokinetics in healthy volunteers
    Hoffman, Justin T.
    Loi, Cho-Ming
    O'Gorman, Melissa
    Plotka, Anna
    Kosa, Maha
    Jakubowska, Anna
    Wang, Diane D.
    CANCER RESEARCH, 2016, 76
  • [9] A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects
    Thai, Ching
    Tayo, Bola
    Critchley, David
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (11): : 1279 - 1289
  • [10] Pharmacokinetic Interaction between Maraviroc and Fosamprenavir-Ritonavir: an Open-Label, Fixed-Sequence Study in Healthy Subjects
    Vourvahis, Manoli
    Plotka, Anna
    da Costa, Laure Mendes
    Fang, Annie
    Heera, Jayvant
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) : 6158 - 6164
12345